AbCellera Announces Expanded Research Collaboration with Teva
Collaboration extends initial partnership and aims to generate lead antibody candidates against membrane targets using AbCellera's antibody discovery platform
VANCOUVER, British Columbia, June 13, 2017 (GLOBE NEWSWIRE) -- AbCellera Biologics, Inc. announced today a new therapeutic antibody discovery collaboration with Teva Pharmaceutical Industries, Ltd. Under the agreement, which builds on a successful first partnership completed in 2016, AbCellera will apply its proprietary monoclonal antibody (mAb) screening platform for the discovery of antibodies that modulate the function of an undisclosed membrane protein target elected by Teva.
Carl Hansen, founding CEO of AbCellera, commented: "We are excited to expand our relationship with the innovative team at Teva. This follow-on project marks an important step in establishing AbCellera's platform as an enabling technology for difficult target classes that have proven intractable by conventional antibody discovery methods."
"We are pleased to extend our work with AbCellera utilizing this company's novel biologics technology," said Steffen Nock, SVP & Global Head of Biologics at Teva. "This agreement will be complementary to our existing antibody discovery process with the potential to strengthen Teva's capabilities in novel biologics discovery."
Under the terms of the agreement, AbCellera will receive an upfront payment and research support, as well as milestone and royalty payments based on Teva's development and commercialization of antibodies generated under this collaboration. Further terms of the agreement are not disclosed.
About AbCellera Biologics, Inc.
AbCellera is a privately held company that develops next-generation monoclonal antibody therapies and provides enabling technologies to biotechnology and pharmaceutical partners. AbCellera's lead technology is a proprietary single-cell antibody discovery and immune profiling platform that allows for high-throughput screening of natural immune repertoires to rapidly identify lead therapeutic antibody candidates from any species, including humans.
Kevin Heyries, PhD
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: AbCellera via Globenewswire
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
Algeco Scotsman Announces Debt Package for Refinancing, Acquisition of Touax Solutions Modulaires SAS and Exercise of Put Option10.12.2017 23:14 | Pressemelding
BALTIMORE, Md., Dec. 10, 2017 (GLOBE NEWSWIRE) -- Algeco/Scotsman Holding S.à r.l. (together with its subsidiaries, the "Algeco Group") today announced that a finance special purpose vehicle that will be a subsidiary of the Algeco Group has entered into a senior debt package arranged by a syndicate of lending institutions and a preferred stock facility with a group of other financing providers. The proceeds of this financing, or any debt issued in lieu of the loans under the facilities (which replacement debt could be in the form of loans, securities or other debt instruments, may be publicly or privately placed and may be denominated in euros or US dollars), will be used to refinance the existing capital structure of the Algeco Group, including its existing Senior Secured Notes due 2018 and existing Senior Unsecured Notes due 2019. In connection with this refinancing, a lending syndicate will provide a new $400 million senior secured asset backed facility. The debt package is continge
Elemica Wins Green Supply Chain Award8.12.2017 19:54 | Pressemelding
WAYNE, Pa., Dec. 08, 2017 (GLOBE NEWSWIRE) -- Elemica, the leading Business Network for the process industries, announces winning the Supply & Demand Chain Executive Green Supply Chain Award for 2017. This is Elemica's 9th consecutive win of this prestigious award that recognizes small, mid-size and large enterprises that leveraged green practices and solutions to further drive sustainable improvements in their supply chain. Elemica was chosen for helping clients improve and achieve measurable sustainability goals through the automation of manual processes, eliminating the use of paper and optimizing transportation processes through carrier collaboration and automated processes that reduce mileage. "This is a great honor for Elemica - recognition for nine consecutive years for helping clients meet their green and sustainability goals," said John Blyzinskyj, CEO of Elemica. "By utilizing Elemica's integrated cloud-based logistics and transportation products, customers have lowere
Constellation Brands to Report Third Quarter Fiscal 2018 Financial Results; Host Conference Call January 5, 20187.12.2017 22:37 | Pressemelding
VICTOR, N.Y., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE:STZ) (NYSE:STZ.B), a leading beverage alcohol company, announced today it will report financial results for its fiscal third quarter ended November 30, 2017, on Friday, January 5, 2018, before the open of the U.S. markets. A conference call to discuss the financial results and outlook will be hosted by President and Chief Executive Officer Rob Sands and Executive Vice President and Chief Financial Officer David Klein at 10:30 a.m. eastern time, January 5, 2018. The conference call can be accessed by dialing +973-935-8505 beginning at 10:20 a.m. (eastern). A live, listen-only webcast of the conference call will be available on the company's website, www.cbrands.com, under the Investors section. Financial information discussed on the conference call, and a reconciliation of reported (GAAP) financial measures with comparable or non-GAAP financial measures, will also be available on the company's websi
CTI Clinical Trial and Consulting Services Announces Acquisition of Eurotrials7.12.2017 21:00 | Pressemelding
COVINGTON, Ky., Dec. 07, 2017 (GLOBE NEWSWIRE) -- CTI Clinical Trial and Consulting Services (CTI), a global, privately held, full-service contract research organization announces the acquisition of Eurotrials, a full-service contract research organization, with more than 20 years of experience, and strong local expertise in Europe and Latin America. The acquisition strengthens CTI's existing Real World Evidence business, adding significant presence and expertise in Europe and Latin America. Eurotrials has offices in Argentina, Brazil, Chile, Mexico, Peru, Portugal and Spain, covering over 15 countries in both regions. Eurotrials provides an extensive array of services from early- to late-stage research as well as product support in accordance with global and specific regional requirements. Additionally, the Eurotrials footprint augments CTI's current reach, enabling CTI to better serve clients and global programs. "We are excited to join our companies together t
DigitalTown Announces Global Launch of CityShares7.12.2017 19:29 | Pressemelding
Local Ownership Model for City Platform Cooperatives built on Blockchain SEATTLE, Dec. 07, 2017 (GLOBE NEWSWIRE) -- DigitalTown, Inc. (OTC PINK:DGTW), the leading provider of People-centric Solutions for Smart Cities, announced today the beginning of the free claim period for CityShares, or fractional interests, in its Smart City platforms across nearly 4 million cities, towns and villages around the world. The announcement makes it possible for any city to become a Smart City based on the DigitalTown platform. A PowerPoint presentation accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/6287d2a9-d481-4e0e-a162-9c3f224daeb1 Since the introduction of DigitalTown in London in June 2017, management at DigitalTown has been in discussions with stakeholders in cities and towns around the world to introduce its flagship Platform Cooperative for Cities. The groundbrea
Crown Bioscience Releases Scientific Posters Detailing Innovations in Preclinical Cancer Pharmacology7.12.2017 16:45 | Pressemelding
Presentation of Posters by Expert Scientists Now Available On-Demand on Crown Bioscience's Website https://www.crownbio.com/eortc17-posters SANTA CLARA, Calif., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, releases scientific posters narrated by leading scientists. These posters were presented at the recent AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and are now available on-demand on Crown Bioscience's website, https://www.crownbio.com/eortc17-posters. Crown Bioscience presented more than a dozen scientific posters describing innovations in the field of preclinical cancer research at AACR-NCI-EORTC 2017. The most compelling work is now available
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom